Ice Miller client relationship manager Georgina Kim was featured in THE BIO article, "Global Big Pharma looks beyond individual assets to execution in licensing deals."

The article included:

“Recently, the criteria major global pharmaceutical companies use to evaluate licensing opportunities have changed dramatically. The days when a promising compound alone was enough to secure a licensing deal worth hundreds of billions of won are over.”

Georgina Kim, Client Relations Manager at Ice Miller LLP, shared this perspective on the evolving landscape of multinational pharmaceutical licensing deals. She explained that, whereas the novelty of a drug candidate was once the ‘primary factor’ driving global licensing decisions, its relative importance has diminished significantly in recent years.

At Ice Miller LLP, a full-service U.S. law firm, Kim supports the global partnering activities of Korean biotechnology companies. The firm focuses on the life sciences and healthcare sectors and provides comprehensive legal counsel covering U.S. market entry, strategic partnerships, mergers and acquisitions (M&A), investment and financing, and intellectual property (IP).

Read the full article.